Stockreport

Immatics Announces First Quarter 2024 Financial Results and Business Update

Immatics N.V. - Ordinary Shares  (IMTX) 
PDF Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME Updated clinical data on ACTengine® IMA203 targe [Read more]